- Salehi M, Aulinger B, Prigeon RL, et al. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes. 2010; 59:1330-1337.
- Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000; 43:1664-1669.
- Muller TD, Finan B, Bloom SR, et al.
Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019; 30:72-130.
- Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1
promotes satiety and suppresses energy intake in humans. J Clin
Invest. 1998; 101:515-520.
- Shah M and Vella A.
Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord.
- Marso SP, Daniels GH,
Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in
type 2 diabetes. N Engl J Med. 2016; 375:311-322.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and
cardiovascular outcomes in patients with type 2 diabetes. N Engl J
Med. 2016; 375:1834-1844.
- Gerstein HC, Colhoun HM,
Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type
2 diabetes (REWIND): a double-blind, randomised placebo-controlled
trial. Lancet. 2019; 394:121-130.
- Bellastella G,
Maiorino MI, Longo M, et al. Glucagon-Like Peptide-1 Receptor
Agonists and Prevention of Stroke Systematic Review of
Cardiovascular Outcome Trials With Meta- Analysis. Stroke. 2020;
- Barkas F, Elisaf M and Milionis H.
Protection against stroke with glucagon-like peptide 1 receptor
agonists: a systematic review and meta-analysis. Eur J Neurol. 2019;
- Clinicaltrials.gov. A Heart Disease
Study of Semaglutide in Patients With Type 2 Diabetes (SOUL).
Available at: https://clinicaltrials.gov/ct2/show/NCT03914326. Last
accessed: December 2020.
- ClinicalTrials.gov. A
Research Study to Compare a Medicine Called Semaglutide Against
Placebo in People With Peripheral Arterial Disease and Type 2
Diabetes (STRIDE). Available at:
https://clinicaltrials.gov/ct2/show/NCT04560998. Last accessed:
- ClinicalTrials.gov. Semaglutide
Effects on Heart Disease and Stroke in Patients With Overweight or
Obesity (SELECT). Available at:
https://clinicaltrials.gov/ct2/show/NCT03574597. Last accessed:
- ClinicalTrials.gov. A Research Study
to See How Semaglutide Works Compared to Placebo in People With Type
2 Diabetes and Chronic Kidney Disease (FLOW). Available at:
https://clinicaltrials.gov/ct2/show/NCT03819153. Last accessed:
Life's a balancing act – life, work, and type 2 diabetes
The continued search for balance
With type 2 diabetes, your body may not respond effectively to a naturally occurring hormone called Glucagon-like peptide 1 (GLP-1). GLP-1 increases insulin levels when it's needed, thereby lowering blood sugar levels. GLP-1 can also reduce food consumption, body weight and increase satiety. Researchers are also looking into the role of GLP-1 in the risk of cardiovascular events, such as heart disease and stroke.
It can be hard for someone with type 2 diabetes to be in tune with their body when it doesn’t respond as well as it should to GLP-1. But, what if your body worked in partnership with you, leaving you more free to focus on other things in life rather than type 2 diabetes?
The Perfect Partner
When your body works in partnership, managing type 2 diabetes can become one less thing to juggle. Whether you are living with type 2 diabetes or care for someone who is – speak to your doctor about treatment options.